Entrada Therapeutics, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2021 | $-8.3M | $-9.2M | $908.0K | $164.0K |
| Jun 2021 | $-7.9M | $-9.5M | $1.5M | $326.0K |
| Sep 2021 | $-14.1M | $-14.9M | $806.0K | $578.0K |
| Dec 2021 | $-20.5M | $-21.9M | $1.3M | $1.5M |
| Mar 2022 | $-21.0M | $-21.6M | $594.0K | $1.8M |
| Jun 2022 | $-18.0M | $-18.8M | $775.0K | $2.5M |
| Sep 2022 | $-27.5M | $-28.3M | $810.0K | $2.7M |
| Dec 2022 | $-27.3M | $-28.0M | $708.0K | $2.9M |
| Mar 2023 | $203.4M | $201.7M | $1.7M | $2.8M |
| Jun 2023 | $-35.1M | $-36.6M | $1.5M | $3.1M |
| Sep 2023 | $-24.5M | $-25.9M | $1.4M | $3.4M |
| Dec 2023 | $-4.0M | $-5.0M | $976.0K | $3.8M |
| Mar 2024 | $-25.5M | $-26.4M | $838.0K | $3.7M |
| Jun 2024 | $39.8M | $38.8M | $1.0M | $4.6M |
| Sep 2024 | $-24.3M | $-24.9M | $639.0K | $4.9M |
| Dec 2024 | $-31.6M | $-32.2M | $635.0K | $4.7M |
| Mar 2025 | $-38.5M | $-39.7M | $1.1M | $5.1M |
| Jun 2025 | $-29.5M | $-29.8M | $275.0K | $5.0M |
| Sep 2025 | $-28.3M | $-28.1M | $-171.0K | $5.1M |
| Dec 2025 | $-32.2M | $-32.0M | $-207.0K | $4.4M |
| Mar 2026 | $-41.7M | $-41.7M | $44.0K | $4.7M |
| Jun 2026 | $-32.5M | $-32.5M | $11.0K | $5.2M |